二甲双胍对2型糖尿病胃癌患者预后的影响：一项基于回顾性队列研究的Meta分析
Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies.
作者信息
Li Lingna, Huang Jianing, Huang Tongmin, Yao Jie, Zhang Yeyuan, Chen Meiling, Shentu Haojie, Lou Haiying
机构信息
Pharmacy Department, The Affiliated Hospital of Ningbo University, Li Huili Hospital, Ningbo, China.
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
出版信息
Int J Endocrinol. 2023 Mar 4;2023:5892731. doi: 10.1155/2023/5892731. eCollection 2023.
BACKGROUND
Metformin is one of the most common drugs for type 2 diabetes mellitus (T2DM) treatment. In addition, metformin intends to have a positive effect on the prognosis of several cancers. However, the therapeutic effect of metformin on gastric cancer (GC) remains controversial. This study explores and updates the therapeutic effect of metformin in GC patients with T2DM.
METHODS
We searched through PubMed, Embase, Web of Science, and the Cochrane Library for relevant articles by July 2022. The relationship between metformin therapy and the prognosis of GC patients with T2DM was evaluated based on the hazard ratio (HR) at a 95% confidence interval (95% CI). Overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were the primary outcomes analyzed.
RESULTS
Seven retrospective cohort studies with a combined 2,858 patients met the inclusion criteria. OS and CSS were reported in six studies, and PFS was reported in four studies. Pooled results showed that, compared to the nonmetformin group, the prolonged OS (HR = 0.72, = 0.001), CSS (HR = 0.81, = 0.001), and PFS (HR = 0.70, = 0.008) of the experimental group may be associated with the exposure to metformin.
CONCLUSION
Metformin may have a beneficial effect on the prognosis of GC patients with T2DM.
背景
二甲双胍是治疗2型糖尿病（T2DM）最常用的药物之一。此外，二甲双胍对几种癌症的预后有积极影响。然而，二甲双胍对胃癌（GC）的治疗效果仍存在争议。本研究探讨并更新二甲双胍对T2DM合并GC患者的治疗效果。
方法
我们检索了截至2022年7月的PubMed、Embase、Web of Science和Cochrane图书馆中的相关文章。基于95%置信区间（95%CI）的风险比（HR）评估二甲双胍治疗与T2DM合并GC患者预后之间的关系。总生存期（OS）、癌症特异性生存期（CSS）和无进展生存期（PFS）是分析的主要结局指标。
结果
七项回顾性队列研究共纳入2858例患者，符合纳入标准。六项研究报告了OS和CSS，四项研究报告了PFS。汇总结果显示，与非二甲双胍组相比，实验组OS延长（HR = 0.72， = 0.001）、CSS延长（HR = 0.81， = 0.001）和PFS延长（HR = 0.70， = 0.008）可能与使用二甲双胍有关。
结论
二甲双胍可能对T2DM合并GC患者的预后有有益影响。
Zotero 插件